Litigation Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals Company GmbH (D. Del. 2019)

Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals Company GmbH (D. Del. 2019)

Docket		Date Filed	2019-04-18
Court	District Court, D. Delaware	Date Terminated	2022-02-09
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,720,001; 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals Company GmbH (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-18				External link to document
2019-04-18	1	Complaint	United States Patent Nos. 9,744,209 (“the ’209 Patent”) and 9,750,785 (“the ’785 Patent”) (collectively…collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of the United States, 35 U.S.…copy of the ’209 Patent is attached as Exhibit A. Par Pharmaceutical owns the ’209 Patent. 23. …copy of the ’785 Patent is attached as Exhibit B. Par Pharmaceutical owns the ’785 Patent. 24. … expiration of the ‘785 Patent, constitutes infringement of the ‘785 Patent under 35 U.S.C. § 271(e)	External link to document
2019-04-18	14	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,375.478 B1 ;US 9,687,526 B2 ;US 9,… 18 April 2019 1:19-cv-00712 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-04-18	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,744,209 B2 ;US 9,750,785 … 18 April 2019 1:19-cv-00712 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Par Pharmaceutical v. Amneal Pharmaceuticals: Vasostrict Patent Litigation Summary, Case No. 1:19-cv-00712

Last updated: August 5, 2026

Par Pharmaceutical, Inc. sued Amneal Pharmaceuticals Company GmbH in the U.S. District Court for the District of Delaware after Amneal filed an abbreviated new drug application seeking approval to market a generic version of Vasostrict, an injectable vasopressin product. The case concerned Orange Book-listed patents covering vasopressin formulations and methods of treatment. The litigation was resolved without a publicly reported merits judgment establishing that Amneal infringed the asserted claims.

What drug and patents were involved in Par v. Amneal?

The case involved Vasostrict, a sterile intravenous vasopressin injection marketed by Par Pharmaceutical. Vasopressin is used primarily to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

Item	Information
Brand product	Vasostrict
Active ingredient	Vasopressin
Dosage form	Sterile injectable solution
NDA	NDA 204485
Plaintiff	Par Pharmaceutical, Inc.
Defendant	Amneal Pharmaceuticals Company GmbH
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-00712
Filing date	April 17, 2019
Statutory basis	Hatch-Waxman patent litigation
Generic filing	Amneal ANDA with Paragraph IV certifications
Principal patents	U.S. Patent Nos. 9,744,791 and 10,485,834

The asserted patents were directed to vasopressin drug products and related therapeutic use. The litigation was not a biologic-biosimilar dispute. It was a small-molecule injectable-drug case governed by the ANDA framework under the Hatch-Waxman Act.

What patents protected Vasostrict in the Amneal litigation?

Par asserted U.S. Patent Nos. 9,744,791 and 10,485,834 against Amneal. The patents were associated with Vasostrict’s formulation and clinical use rather than with a new chemical entity.

U.S. Patent No. 9,744,791

The '791 patent concerned methods and compositions involving vasopressin administration. The patent became relevant to the Federal Circuit’s analysis in related Vasostrict litigation involving claim scope, written-description support, and obviousness.

The patent was part of Par’s strategy to extend protection beyond the earlier composition and formulation patents associated with vasopressin injection. Its commercial value depended on whether generic applicants could design around the claimed concentration, pH, administration, or treatment parameters.

U.S. Patent No. 10,485,834

The '834 patent was a later patent in the Vasostrict estate. It added another layer of patent protection after earlier Vasostrict patents began moving closer to expiration. The patent was asserted against Amneal as part of Par’s effort to delay approval or launch of Amneal’s competing vasopressin product.

Public patent records identify the '791 and '834 patents as part of the Vasostrict-related patent portfolio. Exact Orange Book listing status can change through delisting, patent expiration, corrections, or FDA updates, so the operative listing should be checked against the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database. [1]

Why did Par sue Amneal after the ANDA filing?

Par filed the action under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA containing a Paragraph IV certification as an act of patent infringement for purposes of initiating litigation.

Amneal’s ANDA apparently sought approval for a generic vasopressin injection that Par alleged would infringe the asserted patents if marketed. The complaint triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions and any court order affecting approval timing.

The central commercial issue was whether Amneal could obtain FDA approval and launch before the asserted Vasostrict patents expired or before a negotiated launch date. Because injectable vasopressin products are hospital products, generic entry could affect both Par’s pricing and its institutional market share.

What were the principal legal issues?

The case involved the standard issues in pharmaceutical patent litigation:

1. Whether Amneal’s ANDA product would infringe the asserted claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the patent specifications adequately supported the full scope of the claims.
4. Whether the patents covered the generic product as described in Amneal’s ANDA.
5. Whether Par could obtain an injunction preventing FDA approval or commercial launch.

Infringement

Par’s infringement theory depended on the contents of Amneal’s ANDA and the product characteristics disclosed in that filing. In ANDA cases, the court generally analyzes the proposed generic product as described in the ANDA rather than a later commercial product that may differ from the filing.

For formulation claims, relevant issues can include:

• Vasopressin concentration
• pH range
• Buffering system
• Stabilizing agents
• Container and storage conditions
• Dilution or administration instructions
• Product labeling

For method-of-use claims, the court assesses whether the proposed label encourages or requires the claimed treatment. A generic applicant may attempt to avoid infringement through a skinny label that removes patented indications, but that strategy is less effective when the patented use is inseparable from the approved product’s principal labeling or dosing instructions.

Validity

The validity analysis focused on whether the claimed vasopressin formulation and treatment parameters were disclosed or suggested by the prior art and whether the patent specification supported the claimed scope.

The Federal Circuit’s 2020 decision in related Par Vasostrict litigation addressed patent-validity and claim-construction issues involving the Vasostrict portfolio. The decision is relevant because it illustrates the technical vulnerabilities of formulation patents: seemingly narrow limitations such as pH, concentration, or stability may determine both infringement and validity. [2]

A formulation patent can be commercially valuable even when it does not cover the active ingredient itself. Its strength depends on whether the claimed formulation is difficult to design around and whether the prior art discloses the claimed combination with a reasonable expectation of success.

What was the litigation timeline?

Date	Event
April 17, 2019	Par filed the complaint against Amneal in the District of Delaware.
2019	The case proceeded under the Hatch-Waxman framework following Amneal’s ANDA and Paragraph IV certifications.
2019-2020	The parties litigated claim construction, infringement, validity, and potential approval or launch restrictions.
June 2020	The Federal Circuit issued a related decision concerning Par’s Vasostrict patent litigation and the validity or scope of asserted claims. [2]
Subsequent proceedings	The Amneal action was resolved and closed without a publicly reported final merits decision determining that Amneal’s product infringed the asserted patents.

The docket should be distinguished from other Par Vasostrict cases. Par filed multiple actions against generic applicants, and the Federal Circuit’s related opinion did not necessarily resolve every defendant-specific proceeding.

What was the Orange Book status of Vasostrict?

Vasostrict was listed in the FDA Orange Book with patent information submitted by the NDA holder. The relevant patents were used by Par to support patent litigation against ANDA applicants.

Orange Book-listed patents can create a regulatory delay even when the patents do not cover the active ingredient itself. The statutory stay generally delays final FDA approval for up to 30 months after service of the Paragraph IV notice, unless the court resolves the case earlier or another statutory event applies. [3]

The regulatory significance of the patents depended on:

• Whether each patent remained listed when Amneal filed its ANDA.
• Whether Amneal certified Paragraph IV to each listed patent.
• Whether Par filed suit within 45 days of receiving the notice.
• Whether the FDA imposed or lifted the 30-month stay.
• Whether the parties entered a settlement affecting the approval or launch date.

Did Amneal file a Paragraph IV challenge?

The case was filed as Hatch-Waxman ANDA litigation, which indicates that Amneal made patent certifications that created a basis for Par’s infringement action. The asserted claims were challenged through the ANDA process rather than through a post-launch infringement action.

A Paragraph IV certification is not a finding that a patent is invalid or not infringed. It is a legal position by the ANDA applicant that the relevant patent should not block approval because the patent is invalid, unenforceable, or will not be infringed by the proposed product.

The commercial effect is significant. A successful Paragraph IV challenge can accelerate generic entry. A failed challenge can preserve the branded product’s market position until patent expiration or an agreed launch date.

Was there a final judgment on infringement or validity?

No publicly reported merits judgment in the Amneal action established that Amneal infringed the asserted Vasostrict patents or that those patents were valid and enforceable against Amneal.

The proceeding was resolved through a termination of the case rather than a reported trial verdict. Publicly available docket materials do not provide a detailed public explanation of the commercial terms. As a result, the case should not be characterized as a judicial confirmation of Par’s patent rights against Amneal.

This distinction matters for portfolio valuation. A dismissal or settlement can preserve a branded company’s negotiated market position, but it does not create the same precedent as a favorable claim-construction ruling, infringement judgment, or validity decision.

Did Par and Amneal enter a settlement agreement?

The case ended without a publicly reported trial judgment. The docket resolution is consistent with a negotiated disposition, but the detailed settlement terms were not publicly reported in the core docket materials.

A Hatch-Waxman settlement may address:

• The earliest date Amneal may launch.
• The scope of Amneal’s FDA-approved label.
• Supply or licensing arrangements.
• A covenant not to sue.
• Patent litigation dismissal.
• Allocation of litigation costs.
• Restrictions on launching before a specified patent event.

The absence of public terms prevents a reliable determination of whether the agreement included an authorized generic arrangement, a license, a payment, or a specific launch date.

What was the commercial impact of the litigation?

The case placed a generic injectable vasopressin competitor against Par’s Vasostrict franchise. The commercial exposure was meaningful because Vasostrict had been a major hospital-product asset for Par, and generic competition could reduce average selling prices, formulary access, and purchasing-contract leverage.

The main revenue risks were:

• Entry by Amneal after FDA approval.
• Entry by other ANDA applicants pursuing the same product.
• Hospital substitution and group-purchasing contracts.
• Price erosion following multiple generic approvals.
• Loss of exclusivity for formulation and treatment patents.
• Reduced value of later-filed method-of-use patents.

The case did not involve biosimilar competition. Vasopressin is a synthetic peptide drug regulated through the ANDA pathway, not a biologic subject to the Biologics Price Competition and Innovation Act biosimilar pathway.

How strong was Par’s Vasostrict patent estate?

Par’s Vasostrict patent estate had moderate commercial strength but was more vulnerable than a portfolio centered on a compound patent.

Strengths

• The patents addressed product characteristics that may be present in the approved drug and generic ANDAs.
• Orange Book listing created regulatory leverage.
• Injectable formulations can be difficult to reproduce consistently at commercial scale.
• Method-of-use claims can restrict label-based design-around strategies.
• Multiple patents extended protection beyond earlier Vasostrict rights.

Weaknesses

• The patents did not provide broad composition-of-matter exclusivity over vasopressin.
• Formulation limitations can be attacked through prior-art combinations.
• Narrow pH, concentration, or stability claims may face written-description and obviousness challenges.
• Generic applicants can sometimes modify excipients, labeling, or storage conditions.
• Multiple defendants can create inconsistent litigation outcomes and settlement pressure.

The Federal Circuit’s related Vasostrict decision shows that Par’s portfolio faced substantive validity and claim-scope scrutiny. [2] For investors and licensing counterparties, the relevant question is not simply how many patents were listed, but whether the claims read on competing products and remain defensible against obviousness challenges.

What generic entry risks existed for Vasostrict?

The generic-entry risk was layered rather than binary.

Risk category	Assessment
Compound patent risk	Limited, because vasopressin was not protected by a new chemical entity patent held by Par.
Formulation patent risk	Material, but dependent on claim construction and the generic’s exact formulation.
Method-of-use risk	Dependent on the approved label and whether the generic could omit patented uses.
Regulatory delay	Material because of the Paragraph IV litigation and 30-month stay framework.
Manufacturing risk	Moderate for a sterile injectable product, with facility, process, and quality requirements.
Competitive risk	High if multiple ANDA applicants obtained approval or settled for early entry.
Biosimilar risk	Not applicable.

Sterile injectable manufacturing can delay market entry even after patent litigation ends. FDA approval requires satisfactory manufacturing controls, product quality, facility compliance, and labeling. Patent clearance alone does not guarantee immediate commercial launch.

How did Par v. Amneal compare with other Vasostrict litigation?

Par pursued similar patent claims against other generic applicants. The cases shared the same commercial objective but could produce different outcomes based on each ANDA’s formulation, proposed labeling, and Paragraph IV positions.

Issue	Par v. Amneal	Other Vasostrict ANDA cases
Product	Generic vasopressin injection	Generic vasopressin injection
Plaintiff	Par Pharmaceutical	Par Pharmaceutical or related rights holders
Legal pathway	Hatch-Waxman	Hatch-Waxman
Core patents	'791 and '834 among asserted rights	Overlapping or related Vasostrict patents
Key defenses	Noninfringement and invalidity	Noninfringement, invalidity, and regulatory defenses
Outcome value	Defendant-specific resolution	Potentially different trial or settlement results
Precedential effect	Limited absent a merits decision	Depends on reported rulings

A favorable result against one ANDA applicant would not automatically establish infringement against every other applicant. Generic formulations and labels may differ in legally relevant ways.

What is the current legal significance of the case?

The case is closed and does not provide a reported final merits judgment against Amneal. Its principal significance is strategic:

1. It shows how Par used later-issued formulation and method patents to protect Vasostrict after earlier exclusivity periods approached expiration.
2. It confirms the importance of ANDA-specific analysis in injectable-drug litigation.
3. It illustrates the limits of relying on Orange Book listings without a final infringement or validity ruling.
4. It places the Federal Circuit’s related Vasostrict analysis in the commercial context of generic entry.
5. It does not establish that Amneal was barred permanently from marketing a vasopressin product.

Key Takeaways

• Par sued Amneal in Delaware in April 2019 over an ANDA for generic Vasostrict.
• The dispute involved vasopressin injection and patents including U.S. Patent Nos. 9,744,791 and 10,485,834.
• The case was a Hatch-Waxman Paragraph IV action, not a biosimilar dispute.
• The asserted rights focused on formulation and treatment protection rather than a new chemical entity patent.
• The litigation ended without a publicly reported merits judgment against Amneal.
• Public materials do not establish the detailed economic terms or launch date under any settlement.
• The Vasostrict estate had commercial value but faced formulation-patent validity, claim-scope, and design-around risks.
• Sterile injectable manufacturing and FDA compliance remained separate barriers after patent resolution.

FAQs About Par Pharmaceutical v. Amneal

What product was at issue in Par Pharmaceutical v. Amneal?

The case concerned Amneal’s proposed generic version of Vasostrict, a vasopressin injection product marketed by Par Pharmaceutical.

Which court handled Case No. 1:19-cv-00712?

The case was filed in the U.S. District Court for the District of Delaware.

Did Par win the Vasostrict case against Amneal?

There was no publicly reported final merits judgment holding that Amneal infringed the asserted patents. The action was resolved and closed without a reported trial decision.

Were the asserted Vasostrict patents formulation patents?

The asserted rights included patents directed to vasopressin product characteristics and therapeutic use. They were not equivalent to broad composition-of-matter protection for vasopressin itself.

Does the case create a biosimilar risk for Vasostrict?

No. Vasopressin is addressed through the ANDA generic-drug pathway. Biosimilar litigation under the BPCIA does not apply to this case.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

2. Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals, LLC, 960 F.3d 1378 (Fed. Cir. 2020).

3. U.S. Code. (2023). 21 U.S.C. § 355(j). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov

5. U.S. District Court for the District of Delaware. (2019). Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals Company GmbH, No. 1:19-cv-00712, docket records.